

KASHYAP TELE-MEDICINES LIMITED

CIN: L29110MH1995PLC085738

Regd. Off.: 2nd Floor, Pushpawati Building No. 2, Girgaon Road, Chandanwadi, Mumbai –400002

Corp. Off. : UL/8, Upper Floor, Suryarath Complex, Panchwati 1st Lane Ambawadi, Ahmedabad,
Gujarat-380006

Phone: +91-6359637788, **Email:** investor.relations@kashyaptele-medicines.com,

Website: www.kashyaptele-medicines.com

12th February, 2025

To,

BSE Limited

Listing Department,
Phiroz Jeejeebhoy Tower,
25th Floor, Dalal Street,
Mumbai-400 001

Scrip Code – 531960

Subject: Outcome of Board Meeting

Dear Sir/Madam,

With reference to the above subject and pursuant to Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”) (as amended), the Board of Directors of the Company at their meeting held today i.e. on Wednesday, 12th February, 2025, which commenced at 11:00 AM and concluded at 12:10 PM, has considered and approved the following business items:

- a) Unaudited Financial Results along with Limited Review Report thereon for the quarter and nine months ended on 31st December, 2024, as prepared in accordance with Regulation 33 of the Listing Regulations and Schedule III of the Companies Act, 2013 read with Companies (Indian Accounting Standards) Rules, 2015 (IND-AS);
- b) Other business items as per the agenda of the Meeting.

Kindly take the above disclosures on your record as compliance with Regulations 30 and 33 of the Listing Regulations.

You are requested to take note of the same.

Thanking you.

Yours faithfully,

For KASHYAP TELE-MEDICINES LIMITED

JYOTI SAHU

COMPANY SECRETARY & COMPLIANCE OFFICER

Encl.: As above


INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM FINANCIAL RESULTS

**TO THE BOARD OF DIRECTORS OF
KASHYAP TELE-MEDICINES LIMITED**

1. We have reviewed the accompanying Statement of **Un-audited Financial Results** of **KASHYAP TELE-MEDICINES LIMITED** (the "Company") for the quarter and nine months ended **December 31, 2024** (the "Statement") attached herewith being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.



For, **Ravi Karia & Associates**
Firm Registration No. 157029W
Chartered Accountants



Ravi Karia
Partner
Membership No. 161201
UDIN: 25161201BMONAJ9345

Place: Ahmedabad
Date: February 12, 2025

KASHYAP TELE-MEDICINES LIMITED

CIN: L29110MH1995PLC085738

Regd. Off.: 2nd Floor, Pushpawati Building No. 2, Girgaon Road, Chandanwadi, Mumbai -400002
 Corp. Off. : UL/8, Upper Floor, Suryarath Complex, Panchwati 1st Lane Ambawadi, Ahmedabad, Gujarat-380006
 Phone: +91-6359637788, Email: investor.relations@kashyaptele-medicines.com
 Website: www.kashyaptele-medicines.com


STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2024

S.No.	Particulars	INR in Lakhs Except EPS					
		Quarter Ended			Nine Month Ended		Year Ended
		31-12-2024 (Unaudited)	30-09-2024 (Unaudited)	31-12-2023 (Unaudited)	31-12-2024 (Unaudited)	31-12-2023 (Unaudited)	31-03-2024 (Audited)
I	Revenue from operations	3.90	5.50	4.55	15.30	15.30	19.20
II	Other Income	-	0.00	-	0.00	-	0.01
III	Total Revenue (I + II)	3.90	5.50	4.55	15.30	15.30	19.21
IV	Expenses						
	(a) Cost of materials consumed	-	-	-	-	-	-
	(b) Purchases of stock-in-trade	-	-	-	-	-	-
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	-	-	-	-	-
	(d) Employee benefits expense	2.25	2.54	2.66	8.57	8.22	12.14
	(e) Finance Cost	-	-	-	-	-	-
	(f) Depreciation and amortisation expense	-	-	-	-	-	-
	(g) Other expenses	1.87	2.52	1.78	6.17	6.77	10.03
	Total expenses	4.12	5.06	4.44	14.74	14.99	22.17
V	Profit / (Loss) Before Tax (III- IV)	(0.22)	0.44	0.11	0.56	0.31	(2.96)
VI	Tax Expense :-						
	(a) Current tax			0.03	-	0.08	-
	(b) Tax relating to previous year			-	-	-	0.04
	Total Tax Expense	-	-	0.03	-	0.08	0.04
VII	Profit / (Loss) for the period (V - VI)	(0.22)	0.44	0.08	0.56	0.23	(3.00)
VIII	Other Comprehensive Income						
	A. Items that will be/will not be reclassified to profit and loss	-	-	-	-	-	-
	B. Income tax relating to items that will be / will not be reclassified to profit and loss	-	-	-	-	-	-
	Total comprehensive income for the period (VII+VIII)	(0.22)	0.44	0.08	0.56	0.23	(3.00)
IX	Paid-up Equity Share Capital (Face Value of Rs. 1/- each)	477.22	477.22	477.22	477.22	477.22	477.22
X	Other Equity excluding revaluation reserves						(413.24)
XI	Earnings per equity share: Basic and diluted	(0.000)	0.001	0.000	0.001	0.000	(0.006)

*Notes Enclosed
 Place : Ahmedabad
 Date : 12th Feb., 2025



For and on behalf of Board of Directors of
 Kashyap Tele - Medicines Limited



Amit Agrawal
 Managing Director
 DIN: 00169061

Notes to Unaudited Financial Results for the quarter and nine months ended 31st December, 2024:

1	The above Unaudited Financial Results of the Company for the quarter and nine months ended 31st December, 2024 have been reviewed & recommended by the Audit Committee and approved by the Board of Directors at their respective meeting held on 12th February, 2025. The same have been subjected to Limited Review by the Statutory Auditor.
2	The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under section 133 of the Companies Act, 2013 and other recognised accounting practices & policies to the extent applicable.
3	The Company is engaged in single segment i.e. 'Software Sales', therefore has only one reportable segment in accordance with Ind AS 108 'operating segments'.
4	A Copy of the aforesaid financial results is also available on the website of BSE Limited (www.bseindia.com) and on the website of the Company (www.kashyaptele-medicines.com).
5	Figures pertaining to previous year/periods have been re-grouped and re-arranged wherever necessary.
6	The Company does not have any subsidiary/associate/joint venture company(ies), as on 31st December, 2024, accordingly Consolidated Financial Statement are not applicable to the Company.

Date : 12th Feb.,2025
Place : Ahmedabad



**For and on behalf of Board of Directors of
For Kashyap Tele - Medicines Limited**



**Amit Agrawal
Managing Director
DIN: 00169061**